reviewNature Reviews Clinical OncologyMay 4, 2016Closed access

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

CBC. BoutrosAAAhmad A. TarhiniÉRÉmilie RoutierOLOlivier LambotteFLFrançois Leroy Ladurie

Institut Gustave Roussy · University of Pittsburgh · +7 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,097
total citations
FWCI
52.35
Percentile
100%
References
110
Citations per year

Authors

17

Topics & keywords

Topics
Keywords
  • Medicine
  • Adverse effect
  • Rash
  • Ipilimumab
  • Nivolumab
  • CTLA-4
  • Oncology
  • Immune system
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.